Abstract:Background: BDP/FF/GB pMDI is a novel triple fixed-dose combination of extra-fine inhalation aerosol beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB). Limited data on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of BDP/FF/GB fixed-dose combination in healthy subjects was available. Purposes: This study aimed to evaluate the pharmacokinetics, pharmacodynamics and safety of BDP/FF/GB pMDI in healthy Chinese subjects. Methods: This is an open-label, parallel-group, randomized, single and multiple dose study. In the single dose group, subjects received single supra-therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 400/24/50 mu g). In the multiple dose group, subjects received therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 200/ 12/25 mu g), twice daily, for 7 consecutive days. Plasma BDP, B17MP, formoterol and GB were determined by a validated ultra performance liquid chromatography method with tandem mass spectrometric detection (UPLC/ MS-MS). Heart rate (HR), QTcF, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated as the surrogate indicators of pharmacodynamic effects. Results: A total of 24 subjects were randomized and 22 (11 in each group) completed the study. The dose adjusted pharmacokinetic profiles of BDP, beclomethasone-17-monopropionate (B17MP, the most active metabolite of BDP), formoterol and GB were overall similar in therapeutic and supra- therapeutic dose group, showing dose proportional increase of the systemic exposure to BDP, B17MP, formoterol and GB. The pharmacodynamic variables were within the normal range and showed no significant difference between the two groups. All the treatment-emergent adverse events (TEAEs) were mild and no severe TEAE was reported. Conclusions: Dose adjusted PK profiles were similar between therapeutic and supra-therapeutic dose for all compounds, nearly dose proportional systemic exposure to B17MP, formoterol and GB after BDP/FF/GB pMDI administration in healthy Chinese subjects. BDP/FF/GB pMDI was safe and well tolerated in healthy Chinese subjects. The PK profiles were comparable to previously published data from Western European healthy Caucasian subjects.

A First-in-human Safety, Tolerability and Pharmacokinetics study of Benapenem in Healthy Chinese Volunteers.

Tolerability and Pharmacokinetics of Biapenem Following Single and Multiple Intravenous Administrations in Healthy Chinese Subjects: an Open-Label, Randomized, Single-Center Study.

Pharmacokinetics of biapenem injection after a single dose administration in Chinese healthy subjects

Pharmacokinetics of Single and Multiple Doses of Biapenem for Injection in Chinese Healthy Volunteers with Intravenous Administration

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment

Biapenem Versus Meropenem In The Treatment Of Bacterial Infections: A Multicenter, Randomized, Controlled Clinical Trial

An established LC-MS/MS method and a developed PK model for the study of pharmacokinetic properties of benapenem in infected mice

Phase I Safety, Tolerability, And Pharmacokinetic Studies Of Tetramethylpyrazine Nitrone In Healthy Chinese Volunteers

A multicenter, open-label, randomized controlled clinical trial to compare biapenem with meropenem in the treatment of bacterial pneumonia and urinary tract infections

A Multicenter Clinical Trial on the Efficacy and Safety of Piperacillin/tazobactam for the Treatment of Patients with Hospital Acquired Pneumonia: Treatment of Hospital Acquired Pneumonia Forum in Huadong Area.

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects

Efficacy and Safety of Biapenem Against Lower Respiratory Tract Infections in Elderly Chinese Patients and Optimal Dosing Regimen Based on Pharmacokinetic/pharmacodynamic Analysis

A First-in-human Study of Brozopentyl Sodium, Following Single and Multiple Ascending Intravenous Infusion in Chinese Healthy Volunteers.

Pharmacokinetics of Meropenem Single Dose Intravenous in Healthy Volunteers

Investigation on the tolerance to cefotaxime/sulbactam in healthy volunteers after a single intravenous infusion administration

Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae.

Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.

Pharmacokinetics, Pharmacodynamics and Safety of a Novel Extrafine BDP/FF/GB Combination Delivered Via Metered-Dose Inhaler in Healthy Chinese Subjects